Published in Lupus on January 01, 1999
Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS). J Neurol (2013) 1.79
Current and future treatment approaches for neuromyelitis optica. Ther Adv Neurol Disord (2011) 1.19
Neuromyelitis optica and pregnancy. J Neurol (2013) 1.06
A descriptive study of prevalence, clinical features and other findings of neuromyelitis optica and neuromyelitis optica spectrum disorder in Khuzestan Province, Iran. Iran J Neurol (2015) 0.89
Pregnancy outcomes in aquaporin-4-positive neuromyelitis optica spectrum disorder. Neurology (2015) 0.76
Ward round: A patient with blurred vision and leg weakness. Malawi Med J (2007) 0.75
Neuromyelitis optica in a pregnant woman with systemic lupus erythematous: A case report. Iran J Neurol (2016) 0.75
[A treatment of neuromyelitis optica (Devic's disease) during pregnancy]. Pan Afr Med J (2016) 0.75
Role of low plasma volume treatment on clinical efficacy of plasmapheresis in neuromyelitis optica. Asian J Transfus Sci (2017) 0.75
Treatment of toxoplasmic encephalitis in patients with AIDS. A randomized trial comparing pyrimethamine plus clindamycin to pyrimethamine plus sulfadiazine. The California Collaborative Treatment Group. Ann Intern Med (1992) 2.57
Cefamandole: antimicrobial activity in vitro of a new cephalosporin. Antimicrob Agents Chemother (1975) 2.38
Prevalence of cutaneous disorders in a population of HIV-infected patients. Southwestern France, 1996. Groupe d'Epidémiologie Clinique du SIDA en Aquitaine. Arch Dermatol (1998) 2.22
A prospective study of criteria for the diagnosis of toxoplasmic encephalitis in 186 AIDS patients. The BIOTOXO Study Group. AIDS (1997) 2.21
Once-daily combination therapy with emtricitabine, didanosine, and efavirenz in human immunodeficiency virus-infected patients. J Infect Dis (2000) 1.78
Comparison of the antibacterial activities of sisomicin and gentamicin against gram-negative bacteria. Antimicrob Agents Chemother (1975) 1.62
Th1 (IL-2, interferon-gamma (IFN-gamma)) and Th2 (IL-10, IL-4) cytokine production by peripheral blood mononuclear cells (PBMC) from patients with systemic lupus erythematosus (SLE). Clin Exp Immunol (1999) 1.62
Pivotal advance: The promotion of soluble DC-SIGN release by inflammatory signals and its enhancement of cytomegalovirus-mediated cis-infection of myeloid dendritic cells. J Leukoc Biol (2010) 1.49
Hypereosinophilic syndrome - lymphocytic variant transforming into peripheral T-cell lymphoma with severe oral manifestations. Oral Surg Oral Med Oral Pathol Oral Radiol (2013) 1.46
HIV-associated non-Hodgkin's lymphomas: clinical characteristics and outcome. The experience of the French Registry of HIV-associated tumors. Ann Oncol (1991) 1.44
Causes of death among HIV-infected patients in the era of highly active antiretroviral therapy, Bordeaux, France, 1998-1999. HIV Med (2002) 1.44
[Seroprevalence of viral hepatitis C in patients with human immunodeficiency virus infection]. Presse Med (1992) 1.42
Surveillance of heterosexually acquired HIV infection and AIDS. Lancet (1995) 1.40
[Recommendations for the use of intravenous thrombolytic therapy in cerebrovascular ischemic accident. French Society of Neurovascular Disorders]. Rev Neurol (Paris) (2000) 1.39
Detection of Toxoplasma gondii by PCR and tissue culture in cerebrospinal fluid and blood of human immunodeficiency virus-seropositive patients. J Clin Microbiol (1995) 1.39
Hepatitis C virus infection with and without cryoglobulinemia as a case of Churg-Strauss syndrome. J Rheumatol (2000) 1.39
Chilblain lupus erythematosus: report of 15 cases. Dermatology (1992) 1.39
Plasma lipids in HIV-infected patients: a prospective study in 95 patients. Eur J Clin Invest (1994) 1.39
Trends and determinants of severe morbidity in HIV-infected patients: the ANRS CO3 Aquitaine Cohort, 2000-2004. HIV Med (2007) 1.36
The relationship among carbon dioxide pneumoperitoneum, vasopressin release, and hemodynamic changes. Anesth Analg (1999) 1.34
Determinants of clinical progression in antiretroviral-naive HIV-infected patients starting highly active antiretroviral therapy. Aquitaine Cohort, France, 1996-2002. HIV Med (2005) 1.32
Kinetics of appearance of neutralizing antibodies in 12 patients with primary or recent HIV-1 infection and relationship with plasma and cellular viral loads. J Acquir Immune Defic Syndr Hum Retrovirol (1996) 1.25
Prevalence and underestimation of pain in HIV-infected patients by physicians: a cross-sectional study in a day care hospital. AIDS (1999) 1.21
[Hematologic and immunologic manifestations of primary cytomegalovirus infections in non-immunocompromised hospitalized adults]. Rev Med Interne (2000) 1.21
The enzymatic antioxidant system in blood and glutathione status in human immunodeficiency virus (HIV)-infected patients: effects of supplementation with selenium or beta-carotene. Am J Clin Nutr (1996) 1.20
Determinants of delayed diagnosis of HIV infection in France, 1993-1995. AIDS (1998) 1.18
Prospective cohort study of the effect of pregnancy on the progression of human immunodeficiency virus infection. The Groupe d'Epidémiologie Clinique Du SIDA en Aquitaine. Obstet Gynecol (1995) 1.17
Carotid intima-media thickness is slightly increased over time in HIV-1-infected patients. HIV Med (2005) 1.15
Latency and reactivation of JC virus in peripheral blood of human immunodeficiency virus type 1-infected patients. J Clin Microbiol (1997) 1.14
Wild-mushroom intoxication as a cause of rhabdomyolysis. N Engl J Med (2001) 1.12
In vitro activities of vancomycin and teicoplanin against coagulase-negative staphylococci isolated from neutropenic patients. Antimicrob Agents Chemother (1990) 1.11
Disseminated Mycobacterium lentiflavum infection in a human immunodeficiency virus-infected patient. J Clin Microbiol (2001) 1.11
Lipodystrophy, metabolic disorders, and human immunodeficiency virus infection: Aquitaine Cohort, France, 1999. Groupe d'Epidémiologie Clinique du Syndrome d'Immunodéficience Acquise en Aquitaine. Clin Infect Dis (2000) 1.09
[Amoebic liver abscess. Study of 20 cases with literature review]. Rev Med Interne (2003) 1.08
Prevalence and factors associated with renal impairment in HIV-infected patients, ANRS C03 Aquitaine Cohort, France. HIV Med (2009) 1.08
[Results of coronary artery surgery in octogenarians]. Arch Mal Coeur Vaiss (2001) 1.08
Pyrimethamine-clarithromycin combination for therapy of acute Toxoplasma encephalitis in patients with AIDS. Antimicrob Agents Chemother (1991) 1.06
Susceptibilities of gram-negative bacteria to combinations of antimicrobial agents in vitro. Antimicrob Agents Chemother (1975) 1.03
Study of human herpesvirus 8 (HHV-8) variants from Kaposi's sarcoma in France: is HHV-8 subtype A responsible for more agressive tumors? J Infect Dis (1998) 1.03
Detection of JC virus DNA in the peripheral blood leukocytes of HIV-infected patients. AIDS (1996) 1.02
Number of deaths among HIV-infected adults in France in 2000, three-source capture-recapture estimation. Epidemiol Infect (2006) 1.02
Prognostic factors of combined viral load and CD4+ cell count responses under triple antiretroviral therapy, Aquitaine cohort, 1996-1998. J Acquir Immune Defic Syndr (2001) 1.01
[In vitro sensitivity of Mycobacterium avium and Mycobacterium xenopi to erythromycin, roxithromycin and doxycycline]. Pathol Biol (Paris) (1989) 1.01
[Molecular mechanisms controlling the cell cycle: fundamental aspects and implications for oncology]. Cancer Radiother (2001) 1.00
Polycythaemia as a complication of transdermal testosterone therapy. Br J Haematol (2000) 1.00
Late central demyelination after Fischer's syndrome: MRI studies. J Neurol Neurosurg Psychiatry (1993) 0.97
Soluble adhesion molecules and endothelial cell damage in HIV infected patients. Thromb Haemost (1997) 0.97
[Anterior uveitis and cidofovir]. J Fr Ophtalmol (2001) 0.96
Course of specific T lymphocyte cytotoxicity, plasma and cellular viral loads, and neutralizing antibody titers in 17 recently seroconverted HIV type 1-infected patients. AIDS Res Hum Retroviruses (1997) 0.96
Hepatitis B or hepatitis C virus infection is a risk factor for severe hepatic cytolysis after initiation of a protease inhibitor-containing antiretroviral regimen in human immunodeficiency virus-infected patients. The APROCO Study Group. Antimicrob Agents Chemother (2000) 0.96
Human immunodeficiency virus type 1 replication within cystic lymphoepithelial lesion of the salivary gland. Am J Clin Pathol (1993) 0.96
Peripheral neuropathy with essential mixed cryoglobulinemia: biopsies from 5 cases. Acta Neuropathol (1988) 0.94
Serum selenium predicts outcome in HIV infection. J Acquir Immune Defic Syndr Hum Retrovirol (1995) 0.93
Diagnostic value of quantitative EEG in Alzheimer's disease. Neurophysiol Clin (2001) 0.93
Intention-to-treat vs. on-treatment analyses of clinical trial data: experience from a study of pyrimethamine in the primary prophylaxis of toxoplasmosis in HIV-infected patients. ANRS 005/ACTG 154 Trial Group. Control Clin Trials (1998) 0.93
Increases in CD3+CD4-CD8- T lymphocytes in AIDS patients with disseminated Mycobacterium avium-intracellulare complex infection. J Infect Dis (1996) 0.92
JC virus meningitis in a patient with systemic lupus erythematosus. Lupus (2005) 0.92
JC virus remains latent in peripheral blood B lymphocytes but replicates actively in urine from AIDS patients. J Infect Dis (1998) 0.91
Risk factors for lactic acidosis in HIV-infected patients treated with nucleoside reverse-transcriptase inhibitors: a case-control study. Clin Infect Dis (2003) 0.90
Herpes zoster and human immunodeficiency virus infection: a cohort study of 101 coinfected patients. Groupe d'Epidémiologie clinique du SIDA en aquitaine. J Infect Dis (1993) 0.90
Foscarnet decreases HIV-1 plasma load. J Acquir Immune Defic Syndr Hum Retrovirol (1998) 0.90